Conflicts of Interest
The authors declare no conflicts of interest.
References
- 1
F. McNab, K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra, “Type I Interferons in Infectious Disease,” Nature Reviews. Immunology 15, no. 2 (2015): 87–103.
- 2
S. Volpi, P. Picco, R. Caorsi, F. Candotti, and M. Gattorno, “Type I Interferonopathies in Pediatric Rheumatology,” Pediatric Rheumatology 14, no. 1 (2016): 35.
- 3
K. Drougkas, R. Smerla, C. Skarlis, and C. P. Mavragani, “STING-Associated Vasculopathy With Onset in Infancy: A Review Focusing on Pathophysiology and Treatment Options,” Journal of Molecular Pathology 4, no. 4 (2023): 294–306.
- 4
Y. Liu, A. A. Jesus, B. Marrero, et al., “Activated STING in a Vascular and Pulmonary Syndrome,” New England Journal of Medicine 371, no. 6 (2014): 507–518.
- 5
D. Eleftheriou and P. A. Brogan, “Genetic Interferonopathies: An Overview,” Best Practice & Research. Clinical Rheumatology 31, no. 4 (2017): 441–459.
- 6
S. Volpi, A. Insalaco, R. Caorsi, et al., “Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome,” Journal of Clinical Immunology 39, no. 5 (2019): 476–485.
- 7
M. L. Frémond, A. Hadchouel, L. Berteloot, et al., “Overview of STING-Associated Vasculopathy With Onset in Infancy (SAVI) Among 21 Patients,” Journal of Allergy and Clinical Immunology. In Practice 9, no. 2 (2021): 803.
